Literature DB >> 15123604

A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus.

Kurt M Bohren1, Varsha Nadkarni, Jian H Song, Kenneth H Gabbay, David Owerbach.   

Abstract

Three SUMO (small ubiquitin-related modifier) genes have been identified in humans, which tag proteins to modulate subcellular localization and/or enhance protein stability and activity. We report the identification of a novel intronless SUMO gene, SUMO-4, that encodes a 95-amino acid protein having an 86% amino acid homology with SUMO-2. In contrast to SUMO-2, which is highly expressed in all of the tissues examined, SUMO-4 mRNA was detected mainly in the kidney. A single nucleotide polymorphism was detected in SUMO-4, substituting a highly conserved methionine with a valine residue (M55V). In HepG2 (liver carcinoma) cells transiently transfected with SUMO-4 expression vectors, Met-55 was associated with the elevated levels of activated heat shock factor transcription factors as compared with Val-55, whereas the levels of NF-kappaB were suppressed to an identical degree. The SUMO-4M (Met) variant is associated with type I diabetes mellitus susceptibility in families (p = 4.0 x 10(-4)), suggesting that it may be involved in the pathogenesis of type I diabetes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15123604     DOI: 10.1074/jbc.M402273200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  118 in total

Review 1.  Human pathogens and the host cell SUMOylation system.

Authors:  Peter Wimmer; Sabrina Schreiner; Thomas Dobner
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 2.  New roles of carboxypeptidase E in endocrine and neural function and cancer.

Authors:  Niamh X Cawley; William C Wetsel; Saravana R K Murthy; Joshua J Park; Karel Pacak; Y Peng Loh
Journal:  Endocr Rev       Date:  2012-03-07       Impact factor: 19.871

3.  Small ubiquitin-like modifier (SUMO) modification mediates function of the inhibitory domains of developmental regulators FOXC1 and FOXC2.

Authors:  Theodora E Danciu; Sergey Chupreta; Osvaldo Cruz; Jennifer E Fox; Malcolm Whitman; Jorge A Iñiguez-Lluhí
Journal:  J Biol Chem       Date:  2012-04-05       Impact factor: 5.157

Review 4.  Cardiac function and disease: emerging role of small ubiquitin-related modifier.

Authors:  Jun Wang
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010-12-31

5.  Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1.

Authors:  Luisa Maria Lois; Christopher D Lima
Journal:  EMBO J       Date:  2005-01-20       Impact factor: 11.598

6.  Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors.

Authors:  Serge Grégoire; Xiang-Jiao Yang
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

7.  SUMOylation attenuates sensitivity toward hypoxia- or desferroxamine-induced injury by modulating adaptive responses in salivary epithelial cells.

Authors:  Ha-Van Nguyen; Jo-Lin Chen; Jenny Zhong; Kwang-Jin Kim; Edward D Crandall; Zea Borok; Yuan Chen; David K Ann
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

8.  Cross-talk between sumoylation and phosphorylation in mouse spermatocytes.

Authors:  Yuxuan Xiao; Benjamin Lucas; Elana Molcho; Margarita Vigodner
Journal:  Biochem Biophys Res Commun       Date:  2017-04-20       Impact factor: 3.575

9.  Inhibition of CDK1 activity by sumoylation.

Authors:  Yuxuan Xiao; Benjamin Lucas; Elana Molcho; Tania Schiff; Margarita Vigodner
Journal:  Biochem Biophys Res Commun       Date:  2016-08-10       Impact factor: 3.575

10.  SUMO-mediated inhibition of glucocorticoid receptor synergistic activity depends on stable assembly at the promoter but not on DAXX.

Authors:  Sam R Holmstrom; Sergey Chupreta; Alex Yick-Lun So; Jorge A Iñiguez-Lluhí
Journal:  Mol Endocrinol       Date:  2008-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.